ESR1 and triple-negative breast carcinoma: RNA editing sites were identified with SPRINT, using RNA-Seq reads as an input: 42 ER+ (Estrogen Receptor—positive) samples, 30 samples from healthy tissue adjacent to ER+ tumors, 42 TNBC (triple-negative breast cancer) samples and 21 samples from healthy tissue adjacent to TNBC tumors.